Inborn errors of carbohydrate metabolism

Liver Disease in Children, Third Edition

Volumn , Issue , 2007, Pages 595-625

  Ghishan, Fayez K ^a   Zawaideh, Mona ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77958135119     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511547409.027     Document Type: Chapter

References (318)

1. Mason HH, Turner ME. Chronic galactosemia. Am J Dis Child 1935;50:359–74.
2. Segal S. Galactosaemia today: the enigma and the challenge. J Inherit Metab Dis 1998;21:455–71.
3. GALTd B (the Galactose-1-Phosphate Uridyl Transferase Mutation Analysis Database Home Page). (Accessed November 2, 2006 at http://www. ich. bris. ac. uk/galtdb/.)
4. Isselbacher KJ, Anderson EP, Kurahashi K, et al. Congenital galactosemia, a single enzymatic block in galactose metabolism. Science 1956; 123: 635–6.
5. Steinmann B, Gitzelmann R, Zachmann M. Hypogonadism and galactosaemia. N Engl J Med 1981;305:464–5.
6. Gitzelmann R. Hereditary galactokinase deficiency, a newly recognized cause of juvenile cataracts. Pediatr Res 1967;1:14–23.
7. Gitzelmann R. Deficiency of uridine diphosphate galactose-4- epimerase in blood cells of an apparently healthy infant. Helv Paediatr Acta 1972;27:125–30.
8. Gitzelmann R, Steinmann B, Mitchell B, et al. Uridine diphosphate galactose-4-epimerase deficiency. IV. Report of eight cases in three families. Helv Paediatr Acta 1977;31:441–52.
9. Holton JB, Gillett MG, Mac Faul R, et al. Galactosemia: a new severe variant due to uridine diphosphate galactose-4- epimerase deficiency. Arch Dis Child 1981;56:885–7.
10. Henderson MJ, Holton JB, Mac Faul R. Further observations in a case of uridine diphosphate galactose-4-epimerase deficiency with a severe clinical presentation. J Inherited Metab Dis 1983;6:17–20.
11. Garibaldi LR, Canine S, Superti-Furga A, et al. Galactosemia caused by generalized uridine diphosphate galactose-4-epimerase deficiency. J Pediatr 1983;103:927–30.
12. Bowling FG, Fraser DK, Clague AE, et al. A case of uridine diphosphate galactose-4-epimerase deficiency detected by neonatal screening for galactosemia. Med J Aust 1986;144: 150–1.
13. Holten, JB. Galactosaemia: pathogenesis and treatment. J Inherit Metab Dis 1996;19:3–7.
14. Hopfer U. Membrane transport mechanisms for hexoses and amino acids in the small intestine. In: Johnson LR, Christensen J, Jackson MJ, eds. Physiology of the gastrointestinal tract. 2nd ed. New York: Raven Press, 1987:1499–526.
15. Sherman JR, Adler J. Galactokinase from E. coli. J Biol Chem 1963;238:873–8.
16. Heinrich MR. The purification and properties of yeast galactokinase. J Biol Chem 1964;239:50–3.
17. Cardini CE, Leloir LF. Enzymatic phosphorylation of galactosamine and galactose. Arch Biochem Biophys 1953;45:55–64.
18. Shin-Buehring YS, Beier T, Tan A, et al. Galactokinase and galactose-1-phosphate uridyltransferase (transferase) and galactokinase in human fetal organs [abstract]. Pediatr Res 1977;11:1012.
19. Tedesco TA. Human galactose-1-phosphate uridyl transferase: purification, antibody production, and comparison of the wild type, Duarte variant, and galactosemic gene products. J Biol Chem 1972;247:6631–6.
20. Flach JE, Reichardt TKV, Elsas LJ. Sequence of ac DNAencoding human galactose-1-phosphate uridyl transferase. Mol Biol Med 1990;7:365–9.
21. Bergren WR, Ng WG, Donnell GN. Uridine diphosphate galactose-4-epimerase in human and other mammalian hemolysates. Biochim Biophys Acta 1973;315:464–72.
22. Knop J, Hansen R. Uridine diphosphate glucose pyrophosphorylase: IV. Crystallization and properties of the enzyme from human liver. J Biol Chem 1970;245:2499–504.
23. Clements R, Weaver J, Winegrad A. The distribution of polyol: NADPoxidoreductase in mammalian tissues. Biochem Biophys Res Commun 1969;37:347–53.
24. Wells W, Pittman T, Egan T. The isolation and identification of galactitol from urine of patients with galactosemia. J Biol Chem 1964;239:3192–5.
25. Gitzelmann R, Curtius HC, Muller M. Galactitol excretion in the urine of a galactokinase deficient man. Biochem Biophys Res Commun 1966;22:437–41.
26. Bergren WR, NG WG, Donnell GN. Galactonic acid in galactosemia: identification in the urine. Science 1972;176:683–4.
27. Segal S, Blair A. Some observations on the metabolism of D-galactose in normal man. J Clin Invest 1961;40:2016–25.
28. Tygstrup N. Determination of the hepatic elimination capacity (LM) of galactose by single injection. Scand J Clin Lab Invest 1966;92 Suppl 18:118–25.
29. Lemaire HG, Mueller-Hill B. Nucleotide sequences of the gal E gene and the gal T gene of E. coli. Nucleic Acid Res 1986;14:7705–11.
30. Tajima J, Nogi Y, Fukasawa T. Primary structure of the Saccharomyces cerevisiae GAL7 gene. Yeast 1985;1:67–77.
31. Reichardt JKV, Woo SLC. Molecular basis of galactosemia: mutations and polymorphisms in the gene encoding human galactose-1-phosphate uridyl transferase. Proc Natl Acad Sci U S A 1991;88:2633–7.
32. Reichardt JKV, Packman S, Woo SLC. Molecular characterization of two galactosemicmutations: correlation ofmutations with highly conserved domains in galactose-1-phosphate uridyl transferase. Am J Hum Genet 1991;49:860–7.
33. Field TL, Reznikoff WS, Frey PA. Galactose-1-phosphate uridyl transferase: identification of histidine-164 and histidine-166 as critical residues by site directed mutagenesis. Biochemistry 1989;28:2094–9.
34. Wang B, Xu Y, Ng WG, et al. Molecular and biochemical basis of galactosemia. Mole Geneti Metab 1998;63:263–9.
35. Reichardt JK, Levy HL, Woo SL. Molecular characterizations of two galactosemic mutations and one polymorphorism: implications for structure-function analysis of human galactose-1- phosphate uridyl transferase. Biochemistry 1992;311:5430–3.
36. Williams JC, Howell RR. Nutrition in inborn errors of carbohydrate metabolism. In: Grand RJ, Sutphen JL, Dietz WH, eds. Pediatric nutrition: theory and practice. Boston: Butterworths. 1987:665–70.
37. Hsia DYY, Walker FA. Variability in the clinical manifestations of galactosemia. J Pediatr 1961;59:872–83.
38. Donnell GN, Collado M, Koch R. Growth and development of children with galactosemia. J Pediatr 1961;58:836–44.
39. Donnell GN, Koch R, Bergren WR. Observations on results of management of galactosemic patients. In: Hsia DYY, ed. Galactosemia. Springfield, IL: Charles C Thomas, 1969:247–68.
40. Nadler HL, Inouye T, Hsia DYY. Clinical galactosemia: a study of fifty-five cases. In: Hsia DYY, ed. Galactosemia. Springfield, IL: Charles C. Thomas, 1969:127.
41. Fishler K, Koch R, Donnell GN, et al. Developmental aspects of galactosemia from infancy to childhood. Clin Pediatr 1980; 19:38–44.
42. Komrower GM, Lee DH. Long-termfollow-up of galactosemia. Arch Dis Child 1970;45:367–73.
43. Komrower GM. Galactosaemia: thirty years on the experience of a generation. J Inherit Metab Dis 1982;5:96.
44. Waggoner DD, Buist NRM, Donnell GH. Long-termprognosis in galactosaemia: results of a survey of 350 cases. J Inherit Metab Dis 1990;13:802–18.
45. Belman AL, Moshe SL, Zimmerman RD. Computered tomographic demonstration of cerebral edema in a child with galactosemia. Pediatrics 1986;78:606–9.
46. Levy HL, Sepe SJ, Shih VE, et al. Sepsis due to Escherichia coli in neonates with galactosemia. N Engl J Med 1977;297:823–5.
47. Litchfield WJ, Wells WW. Effects of galactose on free radical reactions of polymorphonuclear leukocytes. Arch Biochem Biophys 1978;188:26–30.
48. Segal S, Blair A, Roth H. Themetabolism of galactose by patients with congenital galactosemia. Am J Med 1965;38:62–70.
49. Segal S. Disorders of galactose metabolism. In: Stanbury JB, Wyngaarden JB, Frederickson DS, eds. The metabolic basis of inheriteddisease. 4th ed. New York:Mc Graw-Hill, 1978:160–81.
50. Segal S. Disorders of galactose metabolism. In: Stanbury JB, Wyngaarden JB, Frederickson DS, eds. The metabolic basis of inherited disease. 6th ed. New York: Mc Graw-Hill, 1989:453–80.
51. Komrower GM, Schwarz V, Holzel A, et al. A clinical and biochemical study of galactosemia. Arch Dis Child 1956;31:254–64.
52. Holzel A, Komrower GM, Schwarz V. Galactosemia. Am J Med 1957;22:703–11.
53. Holzel A, Komrower GM, Wilson VK. Amino-aciduria in galatosemia. Br Med J 1952;1:194–5.
54. Cusworth DC, Dent CE, Flynn FV. The amino-aciduria in galactosemia. Arch Dis Child 1955;30:150–4.
55. Keppler D, Decker K. Studies on the mechanisms of galactosamine hepatitis: accumulation of galactosamine-1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem 1969;10:219–25.
56. Quan-Ma R, Wells W. The distribution of galactitol in tissues of rats fed galactose. Biochem Biophys Res Commun 1965;20:486–90.
57. Schwarz V. The value of galactose phosphate determinations in the treatment of galactosemia. Arch Dis Child 1960;35:428–32.
58. Quan-Ma R, Wells H, Wells W, et al. Galactitol in the tissues of a galactosemic child. Am J Dis Child 1966;112:477–8.
59. Thier S, Fox M, Rosenberg L, et al. Hexose inhibition of amino acid uptake in the rat kidney cortex slice. Biochim Biophys Acta 1964;93:106–15.
60. Saunders S, Isselbacher KJ. Inhibition of intestinal amino acid transport by hexoses. Biochim Biophys Acta 1965;102:397–409.
61. Fox M, Thier S, Rosenberg L, et al. Impaired renal tubular function induced by sugar infusion in man. J Clin Endocrinol 1964;24:1318–27.
62. Rosenberg L, Weinberg A, Segal S. The effect of high galactose diets on urinary excretion of amino acids in the rat. Biochim Biophys Acta 1961;48:500–5.
63. van Heyningen R. Formation of polyols by the lens of the rat with “sugar” cataract. Nature 1959;184:194–5.
64. Kinoshita JH, Dvornik D, Krami M, et al. The effect of aldose reductase inhibitor on the galactose-exposed rabbit lens. Biochim Biophys Acta 1968;158:472–5.
65. Kinoshita JH, Barber GW, Merola LO, et al. Changes in levels of free amino acids and myo-inositol in the galactose-exposed lens. Invest Ophthalmol 1969;8:625–32.
66. Heffley JD, Williams RJ. The nutritional teamwork approach: prevention and regression of cataracts in rats. Proc Natl Acad Sci U S A 1974;71:4164–8.
67. Dische Z, Zelmenis G, Youlous J. Studies on protein and protein synthesis during the development of galactose cataract. Am J Ophthalmol 1957;44:332–40.
68. Sippel TO. Enzymes of carbohydrate metabolism in developing galactose cataracts of rats. Invest Ophthalmol 1967;6:59–63.
69. Korc I. Biochemical studies on cataracts in galactose-fed rats. Arch Biochem 1961;94:196–200.
70. Sipple TO. Energy metabolism in the lens during development of galactose cataract in rats. Invest Ophthalmol 1966;5:576–82.
71. Kinoshita JH, Merola LO, Tung B. Changes in cation permeability in the galactose-exposed rabbit lens. Exp Eye Res 1968;7: 80–90.
72. Wells W, Pittman T, Wells H, et al. The isolation and identification of galactitol from the brains of galactosemia patients. J Biol Chem 1965;240:1002–4.
73. Wells HJ, Gordon M, Segal S. Galactose toxicity in the chick: oxidation of radioactive galactose. Biochim Biophys Acta 1970;222:327–32.
74. Granett SE, Kozak LP, Mc Intyre JP, et al. Studies on cerebral energy metabolism during the course of galactose neurotoxicity in chicks. J Neurochem 1972;19:1659–70.
75. Knull HR, Lobert PF, Wells WW. Galactose neurotoxicity in chicks: effects on fast axoplasmic transport. Brain Res 1974;79:524–7.
76. Malone J, Wells H, Segal S. Decreased uptake of glucose by brain of the galactose toxic chick. Brain Res 1972;43:700–4.
77. Malone JI, Wells HJ, Segal S. Galactose toxicity in the chick: hyperosmolality. Science 1971;174:952–4.
78. Woolley DW, Gommi BW. Serotonin receptors, IV: specific deficiency of receptors in galactose poisoning and its possible relationship to the idiocy of galactosemia. Proc Natl Acad Sci U S A 1964;52:14–19.
79. Knull HR, Wells WW. Recovery from galactose-induced neurotoxicity in the chick by the administration of glucose. J Neurochem 1973;20:415–22.
80. Tsakiris S, Karagiorgiou H, Schulpis KH. The protective effect of L-Cystine and Glutathione on the adult and aged rat brain (Na+, K+)-ATPase and Mg2+-ATPase activities in galactosemia in vitro. Metab Brain Dis 2005;20:87–95.
81. Kaufman FR, Kogut MD, Donnell GN, et al. Hypergonadotropic hypogonadism in female patients with galactosemia. N Engl J Med 1981;304:994–8.
82. Fraser IS, Russell P, Greco S, et al. Resistant ovary syndrome and premature ovarian failure in young women with galactosemia. Clin Reprod Fertil 1986;4:133–8.
83. Levy HL, Driscoll SG, Porensky RS, et al. Ovarian failure in galactosemia. N Engl J Med 1984;310:50.
84. Roe TF, Hallat JG, Donnell GN, et al. Childbearing by a galactosemic woman. J Pediatr 1971;78:1026–30.
85. Schwarz V, Goldberg L, Komrower GM, et al. Some disturbances of erythrocyte metabolism in galactosemia. Biochem J 1956;62:34–40.
86. Miller LR, Gordon GB, Bensch KG. Cytologic alterations in hereditary metabolic disorders: I. The effects of galactose on galactosemia fibroblasts in vitro. Lab Invest 1968;19:428–36.
87. Kurahashi K, Wahba AJ. Interference with growth of certain E. coli mutants by galactose. Biochim Biophys Acta 1958;30:298–302.
88. Yarmolinsky MB, Wiesmeyer H, Kalckar HM, et al. Hereditary defects in galactose metabolism in E. colimutants: II. Galactoseinduced sensitivity. Proc Natl Acad Sci U S A 1959;45:1786–91.
89. Xu YK, Kaufman FR, Donnell GN, et al. Radiochemical assay of minute quantities of galactose-1-phosphage uridyl transferase activity in erythrocytes and leukocytes of galactosemia patients. Clin Chim Acta 1995;235:125–36.
90. Koch R, Donnell GN, Fishler K, et al. Galactosemia. In: Kelley VC, ed. Practice of pediatrics. Hagerstown, MD: Harper and Row, 1979:1–14.
91. Brandt MJ. Frequency of heterozygotes for hereditary galactosemia in a normal population. Acta Genet (Basel) 1967;17:289–98.
92. Tedesco TA, Miller KL, Rawnsley BE, et al. Human erythrocyte galactokinase and galactose-1-phosphate uridylyltransferase: a population survey. Am J Hum Genet 1975;27:737–47.
93. Kliegman RM, Sparks JW. Perinatal galactose metabolism. J Pediatr 1985;107:831–41.
94. Scriver CR. Population screening: report of a workshop. Prog Clin Biol Res 1985;163B:89–152.
95. Robbins SL, Cotran RS. Diseases of infancy and childhood. In: Robbins SL, Cotran RS, eds. Pathologic basis of disease. 2nd ed. Philadelphia: WB Saunders, 1979:561–92.
96. Smetana HF, Olen E. Hereditary galactose disease. Am J Clin Pathol 1962;38:3–25.
97. Walker FA, Hsia DYY, Slatis HM, et al. Galactosemia: a study of 27 kindreds in North America. Ann Hum Genet 1962;25:287–311.
98. Kirkman HN, Bynum E. Enzymic evidence of a galactosemic trait in parents of galactosemic children. Ann Hum Genet 1959; 23:117–26.
99. Mellman WJ, Tedesco TA, Feigl P. Estimation of the gene frequency of the Duarte variant of galactose-1-phosphate uridyl transferase. Ann Hum Genet 1968;32:1–8.
100. Ng WG, Xu YK, Kaufman FR, et al. Deficit of uridine diphosphate galactose in galactosaemia. J Inherit Metab Dis 1989;12: 257–66.
101. Manis FR, Cohn LB, Mc Bride-Chang C, et al. A longitudinal study of cognitive functioning in patients with classical galactosaemia, including a cohort treated with oral uridine. J Inherit Metab Dis 1997;20:549–55.
102. Berry GT. The role of polyols in the pathophysiology of galactosemia. Eur J Pediatr 1995;154 Suppl 2:40–4.
103. Pomeranz Y. Interaction between glycolipids and wheat flour macromolecules in bread making. Adv Food Res 1973;20:153–88.
104. Gross KC, Sams CE. Changes in cell wall neutral sugar composition during fruit ripening: a species survey. Phytochemistry 1984;23:2457–61.
105. Jermyn MA, Isherwood FA. Changes in the cell wall of the pear during ripening. Biochem J 1956;64:123–32.
106. Shallenberger RS, Moyer JC. Relationship between changes in glucose, fructose, galactose, sucrose and stachyose and the formation of starch in peas. Agri Food Chem 1961;8:137–40.
107. Weier TE, Benson AA. The molecular organization of chloroplast membranes. Am J Bot 1967;54:389–402.
108. Wood PJ, Siddiqui IR. Isolation and structural studies of a watersoluble galactan from potato (solanum tuberosum) tubers. Carbohydr Res 1972;22:212–20.
109. Fry SC. Phenolic components of the primary cell wall: feruloylated disaccharides of D-galactose and L-arabinose from spinach polysaccharide. Biochem J 1982;203:493–504.
110. Gross KC. Changes in free galactose, myo-inositol and other monosaccharides in normal and non-ripening mutant tomatoes. Phytochemistry 1983;22:1137–9.
111. Walter JH, Collins JE, Leonard JV. Recommendations for the management of galactosaemia: UK Galactosaemia Steering Group. Arch Dis Child 1999;80:93–6.
112. Gross KC, Acosta PB. Fruits and vegetables are a source of galactose: implications in planning the diets of patients with galactosemia. J Inherit Metab Dis 1991;14:253–8.
113. Gitzelmann R, Auricchio S. The handling of soya alphagalactosides by a normal and a galactosemic child. Pediatrics 1965;36:231–5.
114. Gitzelmann R. Formation of galactose-1-phosphate from uridine diphosphate galactose in erythrocytes from patients and galactosemics. Pediatr Res 1969;3:279–86.
115. Gitzelmann R, Hansen RG. Galactose biogenesis and disposal in galactosemics. Biochim Biophys Acta 1974;372:374–8.
116. Berry GT, Nissim I, Lin Z, et al. Endogenous synthesis of galactose in normal man and patientswith hereditary galactosaemia. Lancet 1995;346:1073–4.
117. Berry GT, Palmieri MJ, Gross KC, et al. The effects of dietary fruits and vegetablesonurinary galactitol excretion in galactose- 1-phosphate uridyltransferase deficiency. J Inherit Metab Dis 1993;16:91–100.
118. Bower BD, Smallpiece V. Lactose-free diet in galactosemia. Lancet 1955;ii:873.
119. Segal S, Cuatrecasas P. The oxidation of 14C galactose by patients with congenital galactosemia: evidence for a direct oxidative pathway. Am J Med 1968;44:340–7.
120. Waisbren SE, Norman RT, Schnell RR, et al. Speech and language deficits in early treated children with galactosemia. J Pediatr 1983;102:75–7.
121. Haberland C, Perou M, Brunngraber EG, et al. The neuropathology of galactosemia: a histopathological and biochemical study. J Neuropathol Exp Neurol 1971;30:431–47.
122. Crome L. A case of galactosemia with the pathological and neuropathological findings. Arch Dis Child 1962;37:415–21.
123. Jan JE, Wilson RA. Unusual late neurological sequelae in galactosemia. Dev Med Child Neurol 1973;15:72–4.
124. Lo W, Packman S, Nash S, et al. Curious neurologic sequelae in galactosemia. Pediatrics 1984;73:309–12.
125. Kaufman FR, Donnell GN, Roe TF, et al. Gonadal function in patients with galactosaemia. J Inherited Metab Dis 1986;9: 140–6.
126. Robinson ACR, Dockeray CJ, Cullen MJ, et al. Hypergonadotrophic hypogonadism in classical galactosemia: evidence for defective oogenesis. Br J Obstet Gynaecol 1984;91: 199–200.
127. Tedesco TA, Morrow G, Mellman WJ. Normal pregnancy and childbirth in a galactosemicwoman. J Pediatr 1972;81:1159–61.
128. Fraser IS, Shearman RP, Wilcken B, et al. Failure to identify heterozygotes for galactosaemia in women with premature ovarian failure. Lancet 1987;ii:566.
129. Kaufman FR, Loro ML, Azen C, et al. Effect of hypogonadism and deficient calcium intake on bone density in patients with galactosemia. J Pediatr 1993;123:365–70.
130. Renner C, Razeghi S, Uberall MA, et al. Hormone replacement therapy in galactosaemic twins with ovarian failure and severe osteoporosis. J Inherit Metab Dis 1999;22:194–5.
131. Chacko CM, McCrone L, Nadler HL. A study of galactokinase and glucose-4-epimerase from normal and galactosemic skin fibroblasts. Biochim Biophys Acta 1972;284:552–5.
132. Dahlqvist A, Gamstorp I, Madsen H. A patient with hereditary galactokinase deficiency. Acta Pediatr Scand 1970;59:669–75.
133. Gitzelmann R, Haigis E. Appearance of active UPD-galactose- 4-epimerase in cells cultured fromepimerase-deficient persons. J Inherit Metab Dis 1978;i:41.
134. Ravich WJ, Bayless TM, Thomas M. Fructose: incomplete intestinal absorption in humans. Gastroenterology 1983;84: 26–9.
135. Steinmann B. Personal communication. 136. Kneepkens CMF, Vonk RJ, Fernandes J. Incomplete intestinal absorption of fructose. Arch Dis Child 1984;59:735–8.
136. Khachadurian AK. Nonalimentary fructosuria. Pediatrics 1963; 32:455–7.
137. Taunton OD, Greene HL, Stifel FB, et al. Fructose-1, 6- diphosphatase deficiency, hypoglycemia, and response to folate therapy in a mother and her daughter. Biochem Med 1978;19: 260–76.
138. Sigrist-Nelson K, Hopfer U. Adistinct D-fructose transport systemin isolated brush border membrane. Biochim Biophys Acta 1974;367:247–54.
139. Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol 1996;270:G541–53.
140. Tsutsumi K, Tsunehiro M, Hidaka S, et al. Rat aldolase isozyme gene: cloning and characterization of c DNA for aldolase B messenger RNA. J Biol Chem 1983;258:6537–42.
141. Besmond C, Dreyfus J-C, Gregori C, et al. Nucleotide sequence of a c DNA clone for human aldolase B. Biochem Biophys Res Commun 1983;117:601–9.
142. Rottmann WH, Tolan DR, Penhoet EE. Complete amino acid sequence for human aldolase B derived from c DNA and genomic clones. Proc Natl Acad Sci U S A 1984;81:2738–42.
143. Lench NJ, Telford EA, Andersen SE, et al. An EST and STS-based YAC contig map of human chromosome 9q22. Genomics 1996;38:199–205.
144. Chambers RA, Pratt RTC. Idiosyncrasy to fructose. Lancet 1956;ii:340.
145. Froesch VER, Prader A, Labhart A, et al. Die hereditare Fructoseintoleranz, eine bisher nicht bekannte kongenitale Stoffwechselstorung. Schweiz Med Wochenschr 1957;87:1168–71.
146. Hers HG, Joassin G. Anomaly of hepatic adolase in intolerance to fructose. Enzymol Biol Clin 1961;1:4–14.
147. Penhoet EE, Kochman M, Rutter WJ. Isolation of fructose diphosphate aldolases A, B and C. Biochemistry 1969;8: 4391–5.
148. Mukai T, Yatsuki H, Arai Y, et al. Human aldolase B gene: characterization of the genomic aldolase B gene and analysis of sequences required formultiple polyadenylations. J Biochem 1987;102:1043–51.
149. Tolan DR, Penhoet EE. Characterization of the human aldolase B gene. Mol Biol Med 1986;3:245–64.
150. Cross NCP, Tolan DR, Cox TM. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. Cell 1988;53:881–5.
151. Cross NCP, Franchis RD, Sebastio G, et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. Lancet 1990;335:306–9.
152. Ali M, Rellos P, Cox TM. Hereditary fructose intolerance. JMed Genet 1998;35:353–65.
153. Tolan DR, Brooks CC. Molecular analysis of commonaldolase B alleles for hereditary fructose intolerance in North Americans. Biochem Med Metabol Biol 1992;48:19–25.
154. Lau J, Tolan DR. Screening for hereditary fructose intolerance mutations by reverse dot-blot. Mol Cell Probes 1999;13:35–40.
155. Steinmann B, Gitzelmann R. The diagnosis of hereditary fructose intolerance. Helv Paediatr Acta 1981;36:297–316.
156. Baerlocher K, Gitzelmann R, Steinmann B, et al. Hereditary fructose intolerance in early childhood: a major diagnostic challenge. Survey of 20 symptomatic cases. Helv Paediatr Acta 1978;33:465–87.
157. Odievre M, Gentil C, Gautier M, et al. Hereditary fructose intolerance in childhood. Am J Dis Child 1978;132:605–8.
158. Bell L, Sherwood WG. Current practices and improved recommendations for treating hereditary fructose intolerance. J Am Diet Assoc 1987;87:721–30.
159. Baker L, Winegrad AI. Fasting hypoglycaemia and metabolic acidosis associated with deficiency of hepatic fructose-1, 6- diphosphatase activity. Lancet 1970;ii: 13–16.
160. Levin B, Snodgrass GJAI, Oberholzer VG, et al. Fructosaemia. Observations on seven cases. Am J Med 1968;45:826–38.
161. Cornblath M, Rosenthal IM, Reisner SH, et al. Hereditary fructose intolerance. N Engl J Med 1963;269:1271–8.
162. Froesch ER, Wolf HP, Baitsch H, et al. Hereditary fructose intolerance: an inborn defect of hepatic fructose-1-phosphate splitting aldolase. Am J Med 1963;34:151–67.
163. Perheentupa J, Raivio KO, Nikkila EA. Hereditary fructose intolerance. Acta Med Scand 1972;542 Suppl:65–75.
164. Fox IH, Kelley WN. Studies on the mechanism of fructoseinduced hyperuricemia in man. Metabolism 1972;21:713–21.
165. Narins RG, Weisberg JS, Myers AR. Effects of carbohydrates on uric acid metabolism. Metabolism 1974;23:455–65.
166. Heuckenkamp P-U, Zollner N. Fructose-induced hyperuricaemia. Lancet 1971;ii:808–9.
167. Sahebjami H, Scalettar R. Effects of fructose infusion on lactate and uric acid metabolism. Lancet 1971;i:366–9.
168. van den Berghe G, Bronfman M, Vanneste R, et al. The mechanism of adenosine triphosphate depletion in the liver after a load of fructose: a kinetic study of liver adenylate deaminase. Biochem J 1977;162:601–9.
169. Bode JC, Zelder O, Rumpelt HJ, et al. Depletion of liver adenosine phosphate and metabolic effects of intravenous infusion of fructose or sorbitol in man and in the rat. Eur J Clin Invest 1973;3:436–41.
170. Maenpaa PH, Raivio KO, Kekomaki MP. Liver adenine nucleotides: fructose-induced depletion and its effect on protein synthesis. Science 1968;161:1253–4.
171. Oberhaensli RD, Rajagopalan B, Taylor DJ, et al. Studyof hereditary fructose intolerance by use of 31P magnetic resonance spectroscopy. Lancet 1987;ii:931–7.
172. Morris RC. Fructose induced disruption of renal acidification in patients with hereditary fructose intolerance. J Clin Invest 1965;44:1076–7.
173. Morris RC. Evidence for an acidification defect of the proximal renal tubule in experimental and clinical renal disease. J Clin Invest 1966;45:1048–52.
174. Swales JD, Smith ADM. Adult fructose intolerance. Q J Med 1966;35:455–73.
175. Black JA, Simpson K. Fructose intolerance. Br Med J 1967; 4:138–41.
176. Burton BK, Chacko CM, Nadler HL. Aldolase in cultivated human fibroblasts. Proc Soc Exp Biol Med 1974;146:605–7.
177. Izzo P, Costanzo P, Lupo A, et al. A new human species of aldolase A m RNA from fibroblasts. Eur J Biochem 1987;164:9–13.
178. Gliksman R, Ghosh NR, Cox RP. Comparison of aldolase Iisozymes in placenta, He La cells, and human fibroblast cultures. Enzyme 1977;22:416–19.
179. Shin YS, Rimbock H, Endres W. Fructose-1-phosphate aldolase activity in humanfetal and adult tissues aswell as leukocytes and cultured fibroblasts in hereditary fructose intolerance. J Inherit Metab Dis 1982;5 Suppl:45.
180. Anderson TA. Recent trends in carbohydrate consumption. Annu Rev Nutr 1982;2:113–32.
181. Yudkin J. Sugar and health. Lancet 1987;i:918.
182. Gitzelmann R, Steinmann B, Van den Berghe G. Disorders of fructose metabolism. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, eds. The metabolic basis of inherited disease. 6th ed. New York: Mc Graw-Hill, 1989:399–424.
183. Mock DM, Perman JA, Thaler MM, et al. Chronic fructose intoxication after infancy in childrenwith hereditary fructose intolerance: a cause of growth retardation. NEngl JMed 1983;309:764–70.
184. Shallenberger RS. Occurrence of various sugars in foods. In: Sipple HL, Mc Nutt KW, eds. Sugars in nutrition. New York: Academic Press, 1974:67–80.
185. Hardinge MG, Swarner JB, Crooks H. Carbohydrates in foods. J Am Diet Assoc 1965;46:197–204.
186. Somogyi JC, Trautner K. Der Glukose-, Fructose- und Saccharosegehalt verschiedener Gemusearten. Schweiz Med Wochenschr 1974;104:177–82.
187. Wyke RJ, Rajkovic IA, Eddleston AL, et al. Defective opsonization and complement deficiency in serum from patients with fulminant hepatic failure. Gut 1980;21:643–9.
188. Brauman J, Kentos P, Frisque P, et al. Intolerance hereditaire au fructose chez une femme de 83 ans. Acta Clin Belg 1971;26: 65–77.
189. Gitzelmann R, Steinmann B, Muller-Wiefel DE, et al. Infusionslosungen. Dtsch Med Wochenschr 1983;108:1656.
190. Nordlie RC. Fine tuning of blood glucose concentrations. Trends Biochem Sci 1985;10:70–5.
191. Arion WJ, Lange AJ, Walls HE, et al. Evidence for the participation of independent translocation for phosphate and glucose-6-phosphate in the microsomal glucose-6-phosphatase system: interactions of the system with orthophosphate, inorganic pyrophosphate, and carbonyl phosphate. J Biol Chem 1980;255:10396–406.
192. Burchell A. Molecular pathology of glucose-6-phosphatase. FASEB J 1990;4:2978–88.
193. Schulze HU, Nolte B, Kannler R. Evidence for changes in the conformational status of rat liver microsomal glucose- 6-phosphate: phosphohydrolase during detergent-dependent membrane modification. Effect of p-mercuribenzoate and organomercurial agarose gel on glucose-6-phosphatase of native and detergent-modified microsomes. J Biol Chem 1986; 261:16571–8.
194. Hers HG. The control of glycogen metabolism in the liver. Ann Rev Biochem 1976;45:167–89.
195. von Gierke E. Hepato-nephromegalia glykogenica (Glykogenspeicherkrankheit der Leber und Nieren). Beitr Pathol Anat 1929;82:497–513.
196. Cori GT, Cori CF. Glucose-6-phosphatase of the liver in glycogen storage disease. J Biol Chem 1952;199:661–7.
197. Cori GT. Glycogen structure and enzyme deficiencies in glycogen storage disease. Harvey Lect 1953;48:145–71.
198. Burchell A, Jung RT, Lang CC, et al. Diagnosis of type Ia and Ic glycogen storage diseases in adults. Lancet 1987;i:1059-62.
199. Waddell ID, Lindsay JD, Burchell A. The identification of T2: the phosphate/pyrophosphate transport protein of the hepatic microsomal glucose-6-phosphatase system. FEBS Lett 1988;229:179–82.
200. Burchell A, Waddell ID, Stewart L, et al. Perinatal diagnosis of Type Ic glycogen storage disease. J Inherit Metab Dis 1989;12:315–17.
201. Nordlie RC, Sukalski K, Munoz JM, et al. Type Ic, a novel glycogenosis. J Biol Chem 1983;258:9139–744.
202. Waddell ID, Burchell A. The microsomal glucose-6- phosphatase enzyme of pancreatic islets. Biochem J 1988;255: 471–6.
203. Veiga-da-Cunha M, Gerin I, Chen YT, et al. The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a. Eur J Hum Genet 1999;7:717–23.
204. Brody LC, Abel KJ, Castilla LH, et al. Construction of a transcription map surrounding the BRCA1 locus of human chromosome 17. Genomics 1995;25:238–47.
205. Lei KJ, Shelly LL, Pan CJ, et al. Mutations in the glucose-6- phosphatase gene that cause glycogen storage disease type 1a. Science 1993;262:580–3.
206. Lei KJ, Pan CJ, Shelly LL, et al. Identification of mutations in the gene for glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1a. J Clin Invest 1994;93:1994–9.
207. Pan CF, Lei KJ, Annabi B, et al. Transmembrane topology of glucose-6-phosphatase. J Biol Chem 1998;273:6144–8.
208. Stroppiano M, Regis S, Di Rocco M, et al. Mutations in the glucose-6-phosphatase gene of 53 Italian patients with glycogen storage disease type Ia. J Inherit Metab Dis 1999;22: 43–9.
209. Hiraiwa H, Pan CJ, Lin B, et al. Inactivation of the glucose 6- phosphate transporter causes glycogen storage disease type 1b. J Biol Chem 1999;274:5532–6.
210. Hershkovitz E, Mandel H, Fryman M, et al. The gene for glycogen-storage disease type 1b maps to chromosome 11q23. Am J Hum Genet 1998;62:400–5.
211. Gerin I, Veiga-de-Cunha M, Achouri Y, et al. Sequence of a putative glucose 6-phosphate translocase, mutated in glycogen storage disease type 1b. FEBS Lett 1997;419:235–8.
212. Hers H, Van Hoof F, de Barsy T. glycogen storage disease. In: Stanbury JB, Wyngaarden JB, Frederickson DS, eds. The metabolic basis of inherited disease. 6th ed. New York:Mc Graw- Hill, 1989:425–52.
213. Ghishan FK, Greene HL. Inbornerrors of metabolism that cause permanent injury to the liver. In: Zakim D, Boyer T, eds. Hepatology: a textbook of liver disease. 2nd ed. Philadelphia: WB Saunders, 1990:49:1300–48.
214. Fernandes J, Berger R, Smit GPA. Lactate as a cerebral metabolic fuel for glucose-6-phosphatase deficient children. Pediatr Res 1984;18:335–9.
215. Howell RR, Stevenson RE, Ben-Menachen Y, et al. Hepatic adenomata with type I glycogen storage disease. JAMA 1976;236: 1481–4.
216. Coire CI, Qizilbash AH, Castelli MF. Hepatic adenomata in type Ia glycogen storage disease. Arch Pathol Lab Med 1987;111:166–9.
217. Levine G, Mierau G, Favara BE. Hepatic glycogenosis, renal glomerular cysts and hepatocarcinoma. Am J Pathol 1976;82: PPC-37.
218. Chen Y-T, Coleman RA, Sheinman JI, et al. Renal disease in type I glycogen storage disease. N Engl J Med 1988;318: 7–11.
219. Slonim AE, Lacy WW, Terry AB, et al. Nocturnal intragastric therapy in type I glycogen storage disease: effect on hormonal and amino acid metabolism. Metabolism 1979;28:707–2.
220. Sadeghi-Nejad A, Presente E, Binkiewicz A, et al. Studies in Type I glycogenosis of the liver: the genesis and deposition of lactate. J Pediatr 1974;85:49–55.
221. Fine RN, Strauss J, Connel GN. Hyperuricemia in glycogen storage disease, type I. Am J Dis Child 1966;1125:572–5.
222. Howell RR. The interrelationship of glycogen storage disease and gout. Arthritis Rheum 1965;8:780–4.
223. Howell RR, Ashton DM, Wyngaarden JB. Glucose-6-phosphatase deficiency glycogen storage disease: studies on the interrelationships of carbohydrates, lipid and purine abnormalities. Pediatrics 1962;29:553–9.
224. Howell RR. Hyperuricemia in childhood. Fed Proc 1968; 27:1078–84.
225. Greene HL, Wilson FA, Hefferan S, et al. ATP depletion, a possible role in the pathogenesis ofhyperuricemia in glycogen storage disease, type I. J Clin Invest 1978;62:321–8.
226. Corby DG, Putnam CW, Greene HL. Impaired platelet function in glucose-6-phosphate deficiency. J Pediatr 1974;85: 71–6.
227. Hutton RA, Macnab AJ, Rivers PA. Defects of platelet function associated with chronic hypoglycemia. Arch Dis Child 1976;51:49–55.
228. Bashan N, Hagai R, Potashnik R, et al. Impaired carbohydrate metabolism of polymorphonuclear leukocytes in glycogen storage disease, Ib. J Clin Invest 1988;81:1317–22.
229. McCawley LJ, Korchak HM, Douglas SD, et al. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colonystimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization. Pediatr Res 1994;35:84–90.
230. Parker PH, Burr I, Slonim AE, et al. Regression of hepatic adenomas in type Ia glycogen storage disease with dietary therapy. Gastroenterology 1987;81:534–6.
231. Limmer J, Feig WE, Leupold D, et al. Hepatocellular carcinoma in type I glycogen storage disease. Hepatology 1988;8:531–7.
232. Edelstein G, Hirschman CA. Hyperthermia and ketoacidosis during anesthesia in a child with glycogen storage disease. Anesthesiology 1980;52:90–2.
233. Schwartz R, Ashmore J, Renold AE. Galactose tolerance in glycogen storage disease. Pediatrics 1957;19:585–94.
234. Fernandes J, Huijing F, Van de Kamer JH. A screening method for liver glycogen diseases. Arch Dis Child 1969;44:311–17.
235. Folkman J, Philippart A, Tze WJ, et al. Portacaval shunt for glycogen storage disease: value of prolonged intravenous hyperalimentation before surgery. Surgery 1972;72:306–14.
236. Boley SJ, Cohen MI, Gliedman ML. Surgical therapy of glycogen storage disease. Pediatrics 1970;46:929–32.
237. Starzl TE, Putnam CW, Porter KA, et al. Portal diversion for the treatment of glycogen storage disease in humans. Ann Surg 1973;178:525–39.
238. Borowitz SM, Greene HL, Gay JC, et al. Case report: Comparison of dietary therapy and portacaval shunt in the management of a patient with type Ib glycogen storage disease. J Pediatr Gastroenterol Nutr 1987;6:635–9.
239. Greene HL, Slonim AE, O’Neil Jr JA, et al. Continuous nocturnal intragastric feeding for management of type I glycogen-storage disease. N Engl J Med 1976;294:423–5.
240. Schwenk WF, Haymond MW. Optimal rate of enteral glucose administration in children with glycogen storage disease type I. N Engl J Med 1986;314:682–5.
241. Chen Y-T, Cornblath M, Sidbury JB. Cornstarch therapy in type I glycogen storage disease. N Engl J Med 1984;310:171–5.
242. Moses SW. Pathophysiology and dietary treatment of the glycogen storage diseases. J Pediatr Gastroenterol Nutr 1990;11: 155–74.
243. Folk CC, Greene HL. Dietary management of type Ia glycogen storage disease. J Am Diet Assoc 1984;84:293–301.
244. Fernandes J, Leonard JV, Moses SW, et al. glycogen storage disease: recommendations for treatment. Eur J Pediatr 1988; 147:226–8.
245. Emmett M, Narins RG. Renal transplantation in type I glycogenosis: failure to improve glucose metabolism. JAMA 1978;239:1642–6.
246. Matern D, Seydewitz HH, Bali D, et al. Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 2002;161 Suppl 1:S10–19.
247. Rake JP, Visser G, Labrune P, et al. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 2002;161 Suppl 1: S20–34.
248. Faivre L, Houssin D, Valayer J, et al. Long-termoutcome of liver transplantation in patients with glycogen storage disease type Ia. J Inherit Metab Dis 1999;22:723–32.
249. Matern D, Starzl TE, Arnaout W, et al. Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 1999;158 Suppl 2:S43–8.
250. Panaro F, Andorno E, Basile G, et al. Simultaneous liverkidney transplantation for glycogen storage disease type IA (von Gierke’s disease). Transplant Proc 2004;36:1483–4.
251. Malatack JJ, Finegold DN, Iwatsuki S, et al. Liver transplantation in type I glycogen storage disease. Lancet 1983;i:1073–4.
252. Anderson DC, Mace ML, Brinkley BR, et al. Recurrent infection in glycogenosis Type IB: abnormal neutrophil motility related to impaired redistribution of adhesion sites. J Infect Dis 1981;143:447–59.
253. Beaudet AL, Anderson DC, Michels VV, et al. Neutropenia and impaired neutrophil migration in type IB glycogen storage disease. J Pediatr 1980;97:906–10.
254. Seger R, Steinmann B, Tiefenauer L, et al. Glycogenosis Ib: neutrophil microbicidal defects due to impaired hexosemonophosphate shunt. Pediatr Res 1984;18:297–9.
255. Arion WJ, Wallin BK, Lange AJ. On the involvementof a glucose- 6-phosphate transport system in the function of microsomal glucose-6-phosphatase. Mol Cell Biochem 1975;6:75–83.
256. Ambruso DR, McCabe ERB, Anderson D, et al. Infectious and bleeding complications in patients with glycogenosis Ib. Am J Dis Child 1985;139:691–7.
257. Greene HL, Slonim AE, Burr IM. Type I glycogen storage disease: a metabolic basis for advances in treatment. Adv Pediatr 1979;26:63–92.
258. Kalhan SC, Gilfillan C, Tserng KY, et al. Glucose production in type I glycogen storage disease. J Pediatr 1982;101:159–60.
259. Sidbury JB. The genetics of the glycogen storage diseases. Prog Med Genet 1965;4:32–58.
260. Farber M, Knuppel RA, Binkiewicz A, et al. Pregnancy and von Gierke’s disease. Obstet Gynecol 1976;47:226–8.
261. Michels VV, Beaudet AL. Hemorrhagic pancreatitis in a patient with glycogen storage disease type I. Clin Genet 1980;17: 220–2.
262. Hug G. Glycogen storage diseases. Birth Defects 1976;12:145–75.
263. Howell RR. Theglycogen storage diseases. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, eds. The metabolic basis of inherited disease. 4th ed. New York: Mc Graw-Hill, 1978:137–59.
264. Senior B, Sadeghi-Nejad A. The glycogenoses and other inherited disorders of carbohydrate metabolism. Clin Perinatol 1976;3:79–98.
265. Coleman JE. Metabolic interrelationships between carbohydrates, lipids, and proteins. In: Bondy PK, Rosenberg LE, eds. Diseases of metabolism. 7th ed. Philadelphia: WB Saunders, 1974:107–220.
266. Greene HL, Slonim AE, Burr IM, et al. Type I glycogen storage disease: five years of management with nocturnal intragastric feeding. J Pediatr 1980;96:590–5.
267. Forbes GB. Glycogen storage disease: report of a casewith abnormal glycogen structure in liver and skeletal muscle. J Pediatr 1953;42:645–53.
268. Illingworth B, Cori GT. Structure of glycogens and amylopectins: III. Normal and abnormal human glycogen. J Biol Chem 1952;199:653–60.
269. Illingworth B, Cori GT, Cori CF. Amylo-1, 6-glucosidase inmuscle tissue in generalized glycogen storage disease. J Biol Chem 1956;218:123–9.
270. Bates EJ, Heaton GM, Taylor C, et al. Debranching enzymefrom rabbit skeletal muscle: evidence for the location of two active centres on a single polypeptide chain. FEBS Lett 1975;58:181–5.
271. Gillard BK, Nelson TE. Amylo-1, 6-glucosidase/4-ß-glucanotransferase: use of reversible substrate model inhibitors to study the binding and active sites of rabbitmuscle debranching enzyme. Biochemistry 1977;16:3978–87.
272. Chen Y-T, He J-K, Ding J-H, et al. Glycogen debranching enzyme: purification, antibody characterization, and immunoblot analyses of type III glycogen storage disease. Am J Hum Genet 1987;41:1002–15.
273. van Hoof F, Hers HG. The subgroups of type III glycogenosis. Eur J Biochem 1967;2:265–70.
274. Ding J-H, de Barsy T, Brown BI, et al. Immunoblot analyses of glycogen debranching enzyme in different subtypes of glycogen storage disease type III. J Pediatr 1990;116:95–100.
275. Brown BI. Diagnosis of glycogen storage disease. In:Wanir RA, ed. Congenital metabolic diseases. Basel: Dekker, 1985:227–50.
276. Bao Y, Dawson TL Jr, Chen YT. Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5’ flanking region. Genomics 1996;38: 155–65.
277. Yang-Feng TL, Zheng K, Yu J, et al. Assignment of the human glycogen debrancher gene to chromosome 1p21. Genomics 1992;13:931–4.
278. Bao Y, Yang BZ, Dawson TL, et al. Isolation and nucleotide sequence of human liver glycogen debranching enzyme m RNA: identification ofmultiple tissue-specific isoforms. Gene 1997;197:389–98.
279. Okubo M, Kanda F, Horinishi A, et al. Glycogen storage disease type IIIa: first report of a causative missensemutation (G1448R) of the glycogen debranching enzyme gene found in a homozygous patient. Hum Mutat 1999;14:542–3.
280. Shen J, Bao Y, Liu HM, et al. Mutations in exon 3 of the glycogen debranching enzyme gene are associated with glycogen storage disease type III that is differentially expressed in liver and muscle. J Clin Invest 1996;98:352–7.
281. Levin S, Moses Sw, Chayoth R, et al. Glycogen storage disease in Israel: a clinical, biochemical and genetic study. Isr JMed Sci 1967;3:397–410.
282. Brandt IK, De Luca VA Jr. Type III glycogenosis: a family with an unusual tissue distribution of the enzyme lesion. Am J Med 1966;40:779–84.
283. Brown B, Brown DH. The glycogen storage diseases: types I, III, IV, V, VII, and unclassified glycogenoses. In: Dickens F, Randle PJ, Whelan WJ, ed. Carbohydrate metabolism and its disorders. New York: Academic Press, 1968:123–50.
284. Murase T, Ikeda H, Muro T, et al. Myopathy associated with Type III glycogenosis. J Neurol Sci 1973;20:287–95.
285. van Creveld S, Huijing F. Glycogen storage disease: biochemical and clinical data in sixteen cases. Am J Med 1965;38:554–61.
286. Ugawa Y, Inoue K, Takemura T, et al. Accumulation of glycogen in peripheral nerve axons in adult-onset type III glycogenosis. Ann Neurol 1986;19:294–7.
287. Miller CG, Alleyne GA, Brooks SEH. Case report: gross cardiac involvement in glycogen storage disease type III. Br Heart J 1972;34:862–4.
288. Bost M. Lamyocardiopathie de la glycogenose type III. Arch Fr Pediatr 1979;36:303–9.
289. Alagille D, Odievre M. Inborn errors of metabolism. In: Alagille D, Odievre M, eds. Liver and biliary tract disease in children. New York: John Wiley, 1979:196–242.
290. Hug G, Krill CE Jr, Perrin EV, et al. Cori’s disease (amylo-1, 6- glucosidase deficiency): report of a case in a Negro child. NEngl J Med 1963;268:113–20.
291. Borowitz SM, Greene HL. Case report: cornstarch therapy in a patient with type III glycogen storage disease. J Pediatr Gastroenterol Nutr 1987;6:631–4.
292. Slonim AE, Terry AB, Moran R, et al. Differing food consumption for nocturnal intragastric therapy in Types I and III glycogen storage disease. Pediatr Res 1978;12:512.
293. Andersen DH. Familial cirrhosis of the liver with storage of abnormal glycogen. Lab Invest 1956;5:11–20.
294. Brown BI, Brown DH. Lack of an a-1, 4-glucan: a-1, 4-glucan 6-glycosyl transferase in a case of type IV glycogenosis. Proc Natl Acad Sci U S A 1966;56:725–9.
295. Fernandes J, Huijing F. Branching enzyme-deficiency glycogenosis: studies in therapy. Arch Dis Child 1968;43:347–52.
296. Thon VJ, Khalil M, Cannon JF. Isolation of human glycogen branching enzyme c DNAs by screening complementation in yeast. J Biol Chem 1993;268:7509–13.
297. Bao Y, Kishnani P, Wu J-Y, et al. Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzymegene. JClin Invest 1996;97:941–8.
298. Shen J, Liu HM, McConkie-Rosell A, et al. Prenatal diagnosis of glycogen storage disease type IV using PCR-based DNA mutation analysis. Prenat Diagn 1999;9:837–9.
299. Maruyama K, Suzuki T, Koizumi T, et al. Congenital form of glycogen storage disease type IV: a case report and a review of the literature. Pediatr Int 2004;46:474–7.
300. Ishihara T, Uchino F, Adachi H. Type IV glycogenosis: a study of two cases. Acta Pathol Jpn 1975;25:613–33.
301. Mc Master KR, Powers JM, Hennigar GR Jr, et al. Nervous systeminvolvement in type IV glycogenosis. Arch Pathol Lab Med 1979;103:105–11.
302. Schochet SS, McCormick WF, Zellweger H. Type IV glycogenosis (amylopectinosis): light and electron microscopic observations. Arch Pathol 1970;90:354–63.
303. Howell RR, Kaback MM, Brown BI. Type IV glycogen storage disease: branching enzyme deficiency in skin fibroblasts and possible heterozygote detection. J Pediatr 1971;78:638–42.
304. Ferguson IT, Mahon M, Cumming WJK. Anadult case of Andersen’s disease: type IV glycogenosis. J Neurol Sci 1983;60:337–51.
305. Holmes JM, Houghton CR, Woolf AL. A myopathy presenting in adult life with features suggestive of glycogen storage disease. J Neurol Neurosurg Psychiatr 1960;23:302–11.
306. Torvik A, Dietrichson P, Svaar H, et al. Myopathy with tremor and dementia: a metabolic disorder? Case report with post mortem study. J Neurol Sci 1974;21:181–90.
307. de La Blanchardiere A, Vayssier C, Duboc D, et al. Severe cardiomyopathy revealing amylopectinosis. Two cases in adolescents from the same family. Presse Med 1994;23:1124–7.
308. Das BB, Narkevicz MR, Sokol RJ, et al. Amylopectinosis disease isolated to the heart with normal glycogen branching enzyme activity and gene sequence. Pediatr Transplant 2005;9:261–5.
309. Lossos A, Barash V, Soffer Z, et al. Hereditary branching enzyme dysfunction in adult polyglucosan body disease: a possible metabolic cause in two patients. Ann Neurol 1991;30:655–62.
310. Bruno C, Servidei S, Shanske G, et al. Glycogen branching enzyme deficiency in adult polyglucosan body disease. Ann Neurol 1993;33:88–93.
311. Greene HL, Ghishan FK, Brown B, et al. Hypoglycemia in type IV glycogenosis: hepatic improvement in two patients with nutritional management. J Pediatr 1988;112:55–8.
312. Reed GB Jr, Dixon JFP, Neustein HB, et al. Type IV glycogenosis: patient with absence of a branching enzyme a-1, 4-glucan: a- 1, 4-glucan 6-glycosyl transferase. Lab Invest 1968;19:546–57.
313. Levin B, Burgess EA, Mortimer PE. Glycogen storage disease type IV, amylopectinosis. Arch Dis Child 1968;43:548–55.
314. Holleman LWJ, van der Haar JA, de Vann GAM. Type IV glycogenosis. Lab Invest 1966;15:357–67.
315. Motoi M, Sonobe H, Ogawa K. Two autopsy cases of glycogen storage disease: cirrhotic type. Acta Pathol Jpn 1973;23:211–23.
316. Brass K. Zur histologischen Diagnose der glykogenose Type IV (Amylopektinose). Z Kinderheilkd 1974;117:187–203.
317. Servidei S, Riepe RE, Langston C, et al. Severe cardiopathy in branching enzyme deficiency. J Pediatr 1987;111:51–6.
318. Greene HL, Brown BI, McClenathan DT, et al. A new variant of type IV glycogenosis: deficiency of branching enzyme activity without apparent progressive liver disease. Hepatology 1988;8:302–6.